NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...
Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...
BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral” with a price target of $11, saying that with a cleaner slate, it expects the shares to outperform. The stock closed at $8.49 on April 13. Analyst Dr. Sean...